Previous 10 | Next 10 |
Image source: The Motley Fool. Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q4 2021 Earnings Call Feb 28, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Atea Pharmaceuticals, Inc. (AVIR) Q4 2021 Earnings Call Transcri...
Gainers: Atea Pharmaceuticals (NASDAQ:AVIR) +15%. TaskUs (NASDAQ:TASK) +9%. Workday (NASDAQ:WDAY) +7%. LivePerson (NASDAQ:LPSN) +6%. Sterling Construction Company (NASDAQ:STRL) +5%. Losers: GoodRx Holdings (NASDAQ:GDRX) -30%. Ambarella (NASDAQ:AMB...
Atea Pharmaceuticals press release (NASDAQ:AVIR): Q4 GAAP EPS of $1.34 beats by $0.96. Revenue of $192.2M (+295.1% Y/Y) beats by $81.11M. For further details see: Atea Pharmaceuticals GAAP EPS of $1.34 beats by $0.96, revenue of $192.2M beats by $81.11M
Developing bemnifosbuvir (AT-527), a nucleotide analog, as preferred backbone of combination therapy for COVID-19, progressing to Phase 2 combination clinical trial in 2H 2022 Initiating Phase 2 combination clinical trial of bemnifosbuvir and ruzasvir (RZR) as potential best-i...
ACAD,ACHC,AGM,AMBA,AMRC,OTCPK:AOIFF,APLS,APPF,APTS,ARCT,ARDX,ASXC,ATRA,AVIR,AY,BANX,BIGC,BLFS,BLNK,BRMK,CAPL,CLDX,CO,CSR,CSTL,DAR,DDD,DNMR,DVAX,ENDP,EVA,FATE,FGEN,FRPT,FSK,GAIA,GDRX,GMRE,GOEV,GPOR,GRPN,HHC,HPQ,HRTX,ICAD,KD,LAZR,LCID,MBI,MDXG,MRTX,NKTR,NMFC,NVAX,NVEE,OCUL,OKE,ONTF,OTIC,PDCE,PG...
BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Monday, February 28, 2022 at 4:30 p.m. ET to report financial...
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for severe viral diseases, today announced the appointment of Nancy Gail Berry Agrawal, Ph.D., as Exec...
BOSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for severe viral diseases, today announced that Jean-Pierre Somm...
BOSTON, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that new data highlighting bemnifosbuvir (AT-527) were published in the peer-reviewed journal, Nature Communications , ...
COVID-19 : Planning global Phase 2 outpatient trial for bemnifosbuvir (AT-527) designed to support anticipated combination trials HCV : Obtained from Merck an exclusive worldwide license to ruzasvir (RZR), a Phase 2-ready, oral, potent NS5A inhibitor for developmen...
News, Short Squeeze, Breakout and More Instantly...
Atea Pharmaceuticals Inc. Company Name:
AVIR Stock Symbol:
NASDAQ Market:
Atea Pharmaceuticals Inc. Website:
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barr...
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 20...
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to ...